<DOC>
	<DOC>NCT00559182</DOC>
	<brief_summary>This is a first-in-human trial to establish the safety, tolerability, Recommended Phase II Dose (RP2D), pharmacodynamic, and clinical activity of MK-8033. Parts A and B of the study will determine the maximum tolerated dose (MTD) and RP2D. Part C of the study will be a single panel crossover study to determine the effect of omeprazole, a gastric pH modifier, on the pharmacokinetics of MK-8033.</brief_summary>
	<brief_title>A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)</brief_title>
	<detailed_description />
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Patient must be at least 18 years of age, with adequate organ function, and an Eastern Cooperative Oncology Group (ECOG) performance of &lt;2 Patient must be willing to undergo prestudy and postdose tumor biopsy and have tumor accessible for biopsy (Waived during Parts A and C) Patient is currently using bisphosphonate therapy or has received this therapy in past 6 months Patient has had chemotherapy, radiotherapy, or biological therapy within 4 weeks of study participation Patient has history of cardiac disease Patient with a primary central nervous system tumor Patient has a known psychiatric or substance abuse disorder Patient is pregnant or breastfeeding, or expecting to conceive during the study Patient is known to be Human Immunodeficiency Virus (HIV) positive and the HIV infection is not well controlled Patient has received therapy with a ProtonPump Inhibitor, Histamine2Receptor antagonist or antacid within one week of study participation (Part B only)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>